At present, in NSCLC, the gene with more methylation variation is CDKN2A. Belinsky and colleagues explored the methylation level of the CDKN2A gene or MGMT gene promoter in the body fluids of patients 3 years before clinical diagnosis of NSCLC (37). This evidence concerns the gene MGMT and non-small cell lung carcinoma.